Skip to search formSkip to main contentSkip to account menu

ulipristal

Known as: 11-beta-(4-(dimethylamino)phenyl)-17-hydroxy-19-norpregna-4,9-diene-3,20-dione, 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione 
A selective progesterone receptor modulator with anti-progesterone activity. Ulipristal binds to the progesterone receptor (PR), thereby inhibiting… 
National Institutes of Health

Related topics

Related topics

8 relations

Narrower (4)

CDB 2914EllaVA-2914ulipristal acetate
elective Progesterone Receptor Modulators [MoA]ulipristal acetate 30 MGulipristal acetate 30 MG Oral Tablet [Ella]ulipristal acetate 5 MG

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Progesterone receptor modulators for endometriosis.
BACKGROUND Endometriosis is defined as the presence of endometrial tissue (glands and stroma) outside the uterine cavity. This… 
2014
2014
Synthesis and biological evaluation of 11′ imidazolyl antiprogestins and mesoprogestins
Review
2013
Review
2013
Cost-effectiveness of increased access to emergency contraceptive pills: probably not.
2013
2013
Axitinib dose titration: what's the limiting factor?
2013
2013
The effects of ulipristal on Bax/Bcl-2, cytochrome c, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis.
2010
2010
Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques.
Review
2008
Review
2008
Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry
Background: A number of synthetic steroids are capable of modulating progesterone receptors with a spectrum of activities ranging… 
Review
2008
Review
2008
Selective progesterone receptor modulators 1: use during pregnancy
Background: A large number of synthetic compounds known as selective progesterone receptor modulators can bind to progesterone… 
Review
2007
Review
2007
Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids.
HRA Pharma, under license from the Research Triangle Institute, is developing ulipristal, a progesterone receptor modulator, for… 
Review
2003
Review
2003
Pharmacologic properties of CDB(VA)-2914
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)